Ferry D R, Glossmann H, Kaumann A J
Br J Pharmacol. 1985 Apr;84(4):811-24. doi: 10.1111/j.1476-5381.1985.tb17375.x.
Ventricular preparations from patients with mitral disease and hypertrophic obstructive cardiomyopathy (HOCM) were set up to contract isometrically. Ventricular membrane particles were also prepared and putative calcium channels were labelled with [3H]-nimodipine. Positive staircase was induced by varying the rate of stimulation of isolated strips from 6 min-1 to 120 min-1 in the presence of 6-60 microM (-)-adrenaline or (-)-noradrenaline. (-)-Verapamil 3-5 microM or (+)-verapamil 20-30 microM reversed the force-frequency relationship (i.e. caused negative staircase) in preparations from patients with mitral disease or HOCM. In subendocardial strips of ventricular septum from 5 patients with HOCM paced at 60 min-1, both (-)-verapamil and (+)-verapamil caused cardiodepression. Half-maximal cardiodepression was observed with 0.4 microM (-)-verapamil and with 3 microM (+)-verapamil. [3H]-nimodipine bound to ventricular membrane particles in a saturable, reversible fashion to a high affinity site with an equilibrium dissociation constant of 0.23 nM. The density of these sites was 95 fmol mg-1 of membrane protein. Binding of the tritiated 1,4-dihydropyridine was stereoselectively inhibited by 1,4-dihydropyridine enantiomers and nifedipine. (-)-Verapamil and (+)-verapamil inhibited high affinity [3H]-nimodipine binding in a negative heterotropic allosteric manner with (-)-verapamil being 5 times more potent than (+)-verapamil on an IC50 basis. At a given [3H]-nimodipine concentration, (+)-verapamil inhibited a greater fraction of specific [3H]-nimodipine binding. The allosteric mode of (+)-verapamil inhibition of [3H]-nimodipine binding was confirmed by kinetic studies. (-)-Verapamil shifted (+)-verapamil-binding inhibition curves to the right in an apparently competitive fashion. The inversion of staircase caused by both verapamil enantiomers suggests that they cause a use-dependent channel blockade. The similar potency ratios for binding and for cardiodepression are indicative of a common locus of action for both verapamil enantiomers within the calcium channel.
对二尖瓣疾病和肥厚性梗阻性心肌病(HOCM)患者的心室标本进行等长收缩设置。还制备了心室膜颗粒,并用[3H]-尼莫地平标记假定的钙通道。在6-60微摩尔(-)-肾上腺素或(-)-去甲肾上腺素存在的情况下,通过将离体条带的刺激频率从6次/分钟改变到120次/分钟,诱导出正阶梯现象。3-5微摩尔的(-)-维拉帕米或20-30微摩尔的(+)-维拉帕米可逆转二尖瓣疾病或HOCM患者标本中的力-频率关系(即引起负阶梯现象)。在5例HOCM患者以60次/分钟起搏的室间隔心内膜下条带中,(-)-维拉帕米和(+)-维拉帕米均引起心脏抑制。0.4微摩尔的(-)-维拉帕米和3微摩尔的(+)-维拉帕米可观察到半数最大心脏抑制。[3H]-尼莫地平以可饱和、可逆的方式与心室膜颗粒结合到一个高亲和力位点,平衡解离常数为0.23纳摩尔。这些位点的密度为95飞摩尔/毫克膜蛋白。氚标记的1,4-二氢吡啶的结合被1,4-二氢吡啶对映体和硝苯地平立体选择性抑制。(-)-维拉帕米和(+)-维拉帕米以负性异源性变构方式抑制高亲和力的[3H]-尼莫地平结合,以IC50为基础,(-)-维拉帕米的效力比(+)-维拉帕米高5倍。在给定的[3H]-尼莫地平浓度下,(+)-维拉帕米抑制更大比例的特异性[3H]-尼莫地平结合。动力学研究证实了(+)-维拉帕米抑制[3H]-尼莫地平结合的变构模式。(-)-维拉帕米以明显竞争的方式将(+)-维拉帕米结合抑制曲线向右移动。两种维拉帕米对映体引起的阶梯反转表明它们引起了使用依赖性通道阻滞。结合和心脏抑制的相似效价比表明两种维拉帕米对映体在钙通道内有共同的作用位点。